8-K: Citius Oncology Amends License Agreement with Eisai, Establishes Payment Schedule for LYMPHIR Milestone and Development Costs

Citius Oncology, a subsidiary of Citius Pharmaceuticals, has amended its license agreement with Eisai to establish a payment schedule for outstanding milestone and development costs related to LYMPHIR.

Summary

• Citius Pharmaceuticals' subsidiary, Citius Oncology, has amended its license agreement with Eisai regarding E7777 (LYMPHIR).
• Upon FDA approval of LYMPHIR in August 2024, Citius Oncology owed Eisai a $5.9 million milestone payment.
• Citius Oncology also incurred $8,233,209.77 in development and inventory costs owed to Eisai.
• An aggregate $6,048,052.67 of inventory costs were included as an accrued obligation on Citius Oncologys financial statements for the period ended December 31, 2024.
• Accounts receivable development costs of $185,317.70 were included on Citius Oncologys financial statements for the period ended December 31, 2024.
• The remaining $1,999,839.40 of expense will be included in Citius Oncologys financial statements for the period ended March 31, 2025.
• The amended agreement, dated March 28, 2025, establishes a payment schedule where Citius Oncology will pay Eisai $2,535,317.77 by July 15, 2025.
• Following this, Citius Oncology will make four monthly payments of $2,350,000 each, and a final payment of $2,197,892.07 by December 15, 2025.
• These payments will include interest at a rate of 2% per annum from the original due dates.
• Both parties have released each other from claims related to the original payment terms, except for breaches of the new letter agreement.
• All other terms of the original License Agreement remain in effect.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the agreement provides a structured payment plan, it also highlights existing financial obligations and the incurrence of interest. The resolution of potential legal claims is a positive aspect.

Positives

• The amended agreement provides Citius Oncology with a structured payment plan, potentially easing immediate financial strain.
• The release of claims related to the original payment terms offers Citius Oncology legal certainty, except for breaches of the new agreement.

Negatives

• Citius Oncology is incurring interest at 2% per annum on the outstanding obligations, increasing the total cost.
• The company still needs to allocate significant funds to meet the payment schedule over the next several months.

Risks

• Failure to adhere to the payment schedule outlined in the amended agreement could lead to legal action from Eisai.
• The financial burden of these payments could impact Citius Oncology's ability to invest in other areas of its business.

Future Outlook

The agreement outlines a payment schedule extending to December 15, 2025, indicating a commitment to fulfilling financial obligations related to LYMPHIR's development and commercialization.

Industry Context

This announcement reflects the financial obligations that often arise in the pharmaceutical industry following regulatory approval of a drug, particularly concerning milestone payments to licensors and suppliers.

Comparison to Industry Standards

• Milestone payments are a common feature in pharmaceutical licensing agreements, reflecting the value of regulatory approvals and commercialization rights.
• The 2% interest rate on the outstanding obligations appears to be within the typical range for commercial agreements of this nature.
• Similar agreements can be seen with companies such as Seattle Genetics and Takeda, where milestone payments are triggered upon regulatory approval and sales targets.

Stakeholder Impact

• Shareholders: The payment obligations could impact the company's profitability and cash flow, potentially affecting shareholder value.
• Eisai: Eisai will receive payments according to the agreed-upon schedule, resolving outstanding financial obligations.
• Creditors: The payment schedule could impact Citius Oncology's ability to meet other financial obligations.

Next Steps

• Citius Oncology must adhere to the payment schedule outlined in the amended agreement.
• Citius Oncology will need to allocate funds to meet the payment obligations over the next several months.
• Monitor Citius Oncology's financial statements for the periods ending March 31, 2025, and subsequent quarters to assess the impact of these payments.

Key Dates

Keywords

LYMPHIR, E7777, Eisai, Citius Oncology, Citius Pharmaceuticals, License Agreement, Milestone Payment, FDA Approval, Payment Schedule, Development Costs